Skip to main content

Table 2 Change from baseline in lipoprotein and lipid levels after 6 weeks of treatment (ITT population)

From: Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)

Lipids/lipoproteins Rosuvastatin 10 mg (n = 493) Atorvastatin 20 mg (n = 481) p value*
  Mean baseline level, mg/dL LSM percentage change (SE) Mean baseline level, mg/dL LSM percentage change (SE)  
LDL-C 165.1 -44.6 (0.6) 164.9 -42.7 (0.6) < 0.05
TC 250.9 -30.8 (0.5) 250.9 -30.7 (0.5) ns
HDL-C 50.3 6.4 (0.5) 49.9 3.1 (0.5) < 0.001
TG 178.1 -17.9 (1.2) 180.3 -19.1 (1.2) ns
NonHDL-C 200.6 -40.1 (0.6) 200.9 -38.9 (0.6) ns
LDL-C/HDL-C 3.5 -47.6 (0.7) 3.5 -44.0 (0.7) < 0.001
TC/HDL-C 5.3 -34.6 (0.5) 5.3 -32.3 (0.5) < 0.01
NonHDL-C/HDL-C 4.3 -43.3 (0.6) 4.3 -40.2 (0.7) < 0.001
Lp(a) 32.6 2.1 (3.8) 27.0 13.3 (3.8) < 0.05
ApoB 157.4 -35.2 (0.6) 156.6 -34.1 (0.6) ns
ApoA-I 160.5 4.8 (0.5) 159.6 1.7 (0.5) < 0.001
ApoB/ApoA-I 1.0 -37.6 (0.7) 1.0 -34.6 (0.7) 0.001
  1. ITT, intention to treat; LSM, least-squares mean; SE, standard error of the mean; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; Lp, lipoprotein; Apo, apolipoprotein.
  2. To convert cholesterol inmg/dL tommol/L, multiply by .02586; to convert TG in mg/dL to mmol/L, multiply by .01129.
  3. *p value obtained from analysis of variance comparing rosuvastatin 10 mg with atorvastatin for LSM percentage change in lipid and lipoproteins.